(Reuters) – The U.S Food and Drug Administration said on Monday it had approved Dova Pharmaceuticals Inc’s drug to treat low blood platelet count in chronic liver disease (CLD) patients, who are scheduled to undergo a medical procedure.
Source: Reuters Medical News